Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quercetin in the Prevention of Covid-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05037240
Recruitment Status : Completed
First Posted : September 8, 2021
Last Update Posted : September 8, 2021
Sponsor:
Information provided by (Responsible Party):
Azienda di Servizi alla Persona di Pavia

Brief Summary:
Quercetin is a flavonol, a subclass of flavonoid compounds. Of the flavonol molecules, quercetin is the most abundant in fruit and vegetables. Quercetin flavonol is characterized by 3 crucial properties: antioxidant, anti-inflammatory and immunomodulatory. The combination of these 3 properties makes quercetin an excellent candidate for dealing with situations in which oxidative stress, inflammation and the immune system are involved. The purpose of the study is to evaluate the effectiveness of an oral nutritional supplement based on quercetin in the prevention of Covid-19 infection.

Condition or disease Intervention/treatment Phase
Covid19 Dietary Supplement: Quercetin Combination Product: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months
Actual Study Start Date : January 12, 2021
Actual Primary Completion Date : April 6, 2021
Actual Study Completion Date : May 25, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Quercetin

Arm Intervention/treatment
Active Comparator: Intervention Group Dietary Supplement: Quercetin
Quercetin (500 mg), 2 times a day for 3 months

Placebo Comparator: Placebo Combination Product: Placebo
500 mg, 2 times a day for 3 months




Primary Outcome Measures :
  1. Prevention of Covid-19 infection [ Time Frame: Absence of Covid-19 infection at 3 months ]
    A nasopharyngeal antigenic swab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Absence of Covid-19 infection

Exclusion Criteria:

  • Previous Sars-Cov-2 infection demonstrated with antibody positivity through venous sampling
  • Demonstrated presence of Sars-Cov-2 through a nasopharyngeal antigenic swab before the start of oral nutritional supplementation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05037240


Locations
Layout table for location information
Italy
Mariangela Rondanelli
Pavia, Italy, 27100
Sponsors and Collaborators
Azienda di Servizi alla Persona di Pavia
Layout table for additonal information
Responsible Party: Azienda di Servizi alla Persona di Pavia
ClinicalTrials.gov Identifier: NCT05037240    
Other Study ID Numbers: 1222/01022021
First Posted: September 8, 2021    Key Record Dates
Last Update Posted: September 8, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Quercetin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs